Cinda Biotech (01801) is now up more than 9%. As of press release, it is up 9.02% to HK$41.7, with a turnover of HK$265 million.
The Zhitong Finance App learned that Cinda Biotech (01801) is now up more than 9%. As of press release, it has risen 9.02% to HK$41.7, with a turnover of HK$265 million.
According to the news, Cinda Biotech announced that in the first quarter of 2024, the company achieved a total product revenue of over RMB 1.7 billion, a strong increase of over 60% over the previous year. The overall product portfolio continued to grow rapidly during the quarter, thanks to advantages such as broad indication potential, health insurance coverage and complete access channels. Dabershu (Cindilizumab Injection) continues to achieve strong sales performance and a stable market leading position. Other products have also grown significantly. In particular, new products are growing at an accelerated pace, and their contribution continues to increase.
In addition, Cinda Biotech announced that it will announce about 20 new clinical research data at the 2024 American Society of Clinical Oncology (ASCO) annual meeting, including the company's series of monoclonal antibodies, double antibodies, and antibody conjugate drugs (ADC) in the research pipeline, as well as innovative oncology drugs such as dabershu (cindilizumab injection), and tarretinib (ROS1 inhibitor).